drugset / Trial / NCT02657187
The Neuromuscular Effect of Rocuronium in Patient
RandomizedParallel-groupSingle-blindSupportive care
Summary
Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass.
Timeline
- Start
- 2016-02
- Primary completion
- 2016-07
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rocuronium | Other / unclassified | 0.24 mg/kg | — |
| Subject | Rocuronium | Other / unclassified | 0.32 mg/kg | — |
| Subject | Rocuronium | Other / unclassified | 0.4 mg/kg | — |
| Subject | Rocuronium | Other / unclassified | 0.48 mg/kg | — |
Indications
No indication recorded.